Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Liangliang Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dalian Medical University, Dalian 116044, P.R. China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Antineoplastic Agents, Drug Design, NF-E2-Related Factor 2. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Technology Star Program of Dalian City, Scientific Research Fund of Liaoning Province Education Administration.
Abstract (Originalsprache)
Compared with positive control MRTX849, the synthesized compounds 7g, 7p, 7q, 7r, 7v, and 7y displayed stronger antiproliferative activities against H358 cells with IC50 values of < 1 nM (3D cell culture) and comparable inhibitory potency against KRASG12C. Among them, 7q (MH5) exhibited satisfactory cellular selectivity, moderate pharmacokinetic characters, and good anticancer effects on pancreatic, colorectal cancer xenograft in vivo. Meaningfully, 7q combined with Nrf2 inhibitor ML385 or PARP7 inhibitor RBN-2397 greatly enhanced the sensitivity of 7q against lung cells (H1373) in vivo. Furthermore, combination therapy of 7q with pan-USP inhibitor PR-619 obtained a statistically significant synergistic inhibition of H1373 cell growth in vitro and in vivo. Our findings indicate that 7q may be a promising drug candidate for the treatment of cancers harboring the KRASG12C mutation, and the results of the combination regimen established a pharmacological foundation for addressing drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Dalian Medical University, Dalian 116044, P.R. China.
- School of Science, Westlake University, Hangzhou 310030, P.R. China.
ORCID-Profile: Lixue Chen
Förderung
- Technology Star Program of Dalian City
- Scientific Research Fund of Liaoning Province Education Administration
Zitieren
APA
Tian, L., Han, Q., Qiao, Y., Chu, P., & Chen, L. (2026). Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02703
Vancouver
Tian L, Han Q, Qiao Y, Chu P, Chen L. Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02703
BibTeX
@article{Tian2026,
author = {Tian, Liangliang and Han, Qingxuan and Qiao, Yanlong and Chu, Peng and Chen, Lixue},
title = {Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02703}
}
EUVIMED